Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12253197 | 0.84 | SMN1; SMN2 (0.71) | HPGDGLAKMT2ASMN1; SMN2LMNA | |
| SCHEMBL7220257 | 0.81 | EGFR (0.54) | HPGDKMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3638056 | 0.77 | SLC6A19 (0.49) | KMT2AALDH1A1MEN1 | |
| SCHEMBL7216546 | 0.77 | KMT2A (0.46) | KMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5011517 | 0.77 | EGFR (0.70) | HPGDKMT2AALDH1A1 | |
| SCHEMBL2385951 | 0.76 | SMN1; SMN2 (0.64) | HPGDGLAKMT2ASMN1; SMN2LMNA | |
| SCHEMBL6726303 | 0.75 | EGFR (0.73) | HPGDKMT2AALDH1A1 | |
| SCHEMBL5485829 | 0.75 | EGFR (0.73) | HPGDKMT2AALDH1A1 | |
| SCHEMBL3944541 | 0.75 | RAB9A (0.50) | HPGDKMT2ASMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL364448 | 0.75 | HPGD (0.87) | HPGDMAPK1SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | claimed |
| CN-107580596-B | Sulfimidoylpurine ketone compounds and derivatives for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2020-07-14 | — | — | CN | claimed |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | HOFFMANN-LA ROCHE INC. (US) | 2020-04-09 | — | — | US | claimed |
| EP-3294740-B1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | claimed |
| EP-3294740-A1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2018-03-21 | — | — | EP | claimed |
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | claimed |
| US-9708325-B2 | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | claimed |
| WO-2016180695-A1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-17 | — | — | WO | claimed |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | claimed |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | disclosed |
| CN-107580596-B | Sulfimidoylpurine ketone compounds and derivatives for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2020-07-14 | — | — | CN | disclosed |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | HOFFMANN-LA ROCHE INC. (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3294740-B1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3294740-A1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2018-03-21 | — | — | EP | disclosed |
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-9708325-B2 | Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016180695-A1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-17 | — | — | WO | disclosed |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | PRSS1, TPMT, SULT1E1 | HPGD 2479/4885MAPK1 1550/4885GLA 2429/4885 |
| US-20160326177-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | PRSS1, TPMT, SULT1E1 | HPGD 2479/4885MAPK1 1550/4885GLA 2429/4885 |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | NQO1, UGT1A1, SULT1E1 | HPGD 929/4885MAPK1 2242/4885GLA 1493/4885 |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | NQO1, UGT1A1, SULT1E1 | HPGD 929/4885MAPK1 2242/4885GLA 1493/4885 |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | STS, SULT1E1, SULT1A1 | HPGD 859/4885MAPK1 2201/4885GLA 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.